Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Bullish option flow detected in Teva (TEVA) with 17,095 calls trading, 1.7x expected, and implied vol increasing over 1 point to 42.32%. 3/14 ...

Lumicera Health Services announced today it has secured a purchase agreement with Anda, Inc., an independent wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., for a lower-priced ...

KLN is an Asia -based, global 3PL with a highly diversified business portfolio and extensive coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, ...

Teva Pharmaceutical Industries's price surge today seems to be confirming the bullish analyst outlook on the stock. Ending ...

Teva Pharmaceutical Industries Limited ( NYSE: TEVA) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:00 AM ET Good morning, everyone. My name is Balaji Prasad. I'm the Senior ...

The campaign will feature imagery and video creative across digital retail, owned media, out-of-home placements and paid ...

The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

Research analysts at Zacks Research reduced their Q4 2025 earnings estimates for Teva Pharmaceutical Industries in a research ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva ...

An audio webcast of the fireside chat will also be available to investors and the general public and can be accessed in the Events Section of Alvotech’s Investor Portal. After the event, a recording ...

The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...